BridgeBio

Company research

Public company, workplace, funding, and market signals

Updated Jul 29, 2026

Overview

BridgeBio is a commercial-stage biopharmaceutical company focused on genetic conditions and rare diseases, organized around a decentralized hub-and-spoke model. Its lead marketed product is Attruby (acoramidis) for ATTR-CM.

Primary product

Attruby (acoramidis)

Founded

2015

Headquarters

3160 Porter Drive, Suite 250, Palo Alto, CA 94304, USA

Team size

501-1000

Work style

Flexible

Industry

Biotechnology Research

Sub-industry

Genetic medicines / rare disease biopharmaceuticals

Offices

Palo Alto, California, United States (HQ)

San Francisco, California, United States (office / hybrid roles)

San Carlos, California, United States (role/site location in job postings)

Business model

commercial-stage biopharmaceutical R&D

specialty drug commercialization

decentralized hub-and-spoke operating model

ex-U.S. licensing and royalty monetization

Funding

Stage

public

Total raised

$5.2B

Latest round

Preferred equity financing · Jul 2026

Latest amount

$933.9M

Preferred equity

Jul 2026 · Sixth Street / HealthCare Royalty

$1B

Preferred equity financing

Jul 2026 · Sixth Street

$933.9M

Convertible senior notes due 2033

Jan 2026 · Qualified institutional buyers

$632.5M

Royalty monetization

Jun 2025 · HealthCare Royalty and Blue Owl Capital

$300M

Strategic financing

Jan 2024 · Blue Owl Capital / CPP Investments

$1.3B

Royalty and credit financing

Jan 2024 · Blue Owl Capital and CPP Investments

$1.3B

PIPE

Sep 2023 · Qatar Investment Authority

$250M

Non-dilutive debt financing

Nov 2021 · Syndicate of lenders

$750M

Debt financing / credit facility

Nov 2021 · Syndicate of lenders

$750M

IPO

Jun 2019 · J.P. Morgan / Goldman Sachs / Jefferies / SVB Leerink / KKR

$348.5M

Financing round

Jan 2019 · KKR and Viking Global Investors

$299.2M

Series C financing

Sep 2017 · Viking Global Investors / KKR

$135M

Series D financing

Sep 2017 · Viking Global Investors

$135M

People & investors

Leadership

Neil Kumar

Chief Executive Officer and Founder

Thomas Trimarchi

President and Chief Financial Officer

Uma Sinha

Chief Scientific Officer

Adora Ndu

Chief Regulatory Officer & EVP Portfolio Strategy and Management

Jonathan Fox

Chief Medical Officer, Cardiorenal

Richard Scheller

Chairman of R&D

Matt Outten

Chief Commercial Officer

Founders

Andrew Lo, Ph.D.

Co-founder

Charles Homcy

Founder and Chairman of Pharmaceuticals

Charles Homcy, M.D.

Co-founder

Frank McCormick, Ph.D.

Co-founder

Frank P. McCormick

Founder and Chairman of Oncology

Neil Kumar, Ph.D.

CEO and Founder

Richard Scheller, Ph.D.

Co-founder

Investors

Qatar Investment Authority

Sequoia Capital

Sixth Street

Viking Global Investors

Work & culture

Patient-first, intellectually independent, high-urgency, and data-driven; the company emphasizes challenging convention and letting science speak.

Work style

Flexible

Compensation

Public job posts show California base salary bands such as about $94.8k-$105.2k for Research Associate II and $245k-$275k for Senior Director, Training and Learning Excellence, alongside market-leading pay, equity, and financial reward signals.

Benefits

market-leading pay

comprehensive healthcare

flexible working model

401(k) with employer match

employee stock purchase program (ESPP)

employer-paid medical, dental, and vision coverage for employees and dependents

Spring Health mental health support

unlimited flexible PTO

paid parental leave

subsidized office lunches

LinkedIn Learning

LifeLabs

BetterUp Coaching

peer recognition

growth and internal mobility opportunities

Product & market

Pricing

Specialty prescription-drug pricing with payer reimbursement; some assets are also monetized through licensing and royalties.

Differentiators

—Decentralized hub-and-spoke model for speed and scalability
—Focus on genetic diseases with clear genetic drivers
—Commercial-stage with approved products already on market
—First/best-in-class positioning for several programs
—Centralized shared clinical, regulatory, and commercial capabilities
—Deep academic-partnership sourcing of early science
—Ex-U.S. licensing and royalty monetization to fund growth
—Patient-first culture and rapid execution

Technology

Workday

Microsoft 365

Expensify

Tableau

Okta

Ramp

Power BI

Greenhouse

Marketo

IQVIA

DocuSign

Salesforce

Confluence

Calendly

Veeva Vault eTMF

Google Workspace

Jira

Snowflake

Coupa

Zendesk

Customers

Patients living with genetic diseases and rare conditions

Physicians and specialty clinics treating ATTR-CM, ADH1, LGMD2I/R9, achondroplasia, and other rare diseases

Payers, health systems, and specialty pharmacies

Competitors

Pfizer (tafamidis / Vyndaqel / Vyndamax)

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

Ultragenyx Pharmaceutical

PTC Therapeutics

Scale & contact

Estimated revenue

$500M-$600M

Estimated monthly visits

46.2K

Traffic estimate as of Jul 2026

info@bridgebio.com 650-391-9740

Signals & risks

Layoff

Mar 2022

BridgeBio confirmed layoffs and restructuring amid market pressure and clinical setbacks; the company did not disclose the exact number of affected employees.

Source

Acquisition

Jan 2021

BridgeBio completed its acquisition of the remaining Eidos Therapeutics shares, making Eidos a wholly owned subsidiary and bringing acoramidis commercialization in-house.

Source

Other

Feb 2025

The 2025 annual report states that Truseltiq was withdrawn, indicating a product withdrawal / discontinuation risk signal in the portfolio.

Source

Latest news

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

BridgeBio Pharma, Inc. · Jul 2026

BridgeBio said the FDA accepted the NDA for encaleret in ADH1 and gave a PDUFA target action date of May 8, 2027.

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

BridgeBio Pharma, Inc. · Jul 2026

BridgeBio reported published analyses in Circulation: Heart Failure suggesting kidney-protective effects of acoramidis in ATTR-CM patients.

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

BridgeBio Pharma, Inc. · Jul 2026

BridgeBio announced up to $1 billion of preferred equity led by Sixth Street with participation from HealthCare Royalty, supporting upcoming launches including BBP-418, encaleret, and infigratinib.

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma, Inc. · May 2026

BridgeBio presented new Phase 3 ATTRibute-CM data showing continued clinical benefit and differentiated disease-modifying signals for acoramidis.

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

BridgeBio investor relations · Feb 2026

BridgeBio reported full-year 2025 revenue of $502.1 million, Attruby revenue of $362.4 million, and disclosed $632.5 million of convertible notes issued in January 2026.

Jobs and careers at BridgeBio

74 jobs at BridgeBio

Director, Program Management

On-site

Project Management

San Francisco - 1800 Owens

1d ago

On-site

Full-time